Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Fallopian Tube Cancer Clinical Trial

Official title:

Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03126812
• Other study ID #: N16OPE
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 1, 2017
• Est. completion date: March 5, 2024

Study information

• Verified date: May 2024
• Source: The Netherlands Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for its capacity to induce and broaden T cell responses against tumor neo-antigens.

Description:

Long-term survival in stage IV serous ovarian, peritoneal, and fallopian tube cancer is poor and has not significantly improved over the last decades. Standard treatment consists of debulking surgery and six courses of carboplatin and paclitaxel. Nevertheless, the disease recurs in >90% of women, usually within two years.

Since early observations that the presence of infiltrating T cells is associated with improved outcome, ovarian cancer is linked to a potential benefit of immunotherapy.10 More recently, T cell checkpoint blockade with anti-PD1 and anti-PDL1 have shown promising activity in platinum resistant ovarian cancer with objective and durable responses in 10-20% of patients. This finding raises the question whether anti-PD1 could also play a role in first line treatment of ovarian cancer.

To fully use the power of T cell checkpoint inhibition, sufficient TCR stimulation is required. Importantly, the amount of antigen that can provide this signal will correlate with tumor load, and because of this adjuvant immunotherapy may work most efficiently, when initiated prior to surgery. In addition, we postulate that antigen retrieval will increase after induction treatment with cytotoxic therapy.

To address these questions, we propose a feasibility study in patients with FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer in which we evaluate pembrolizumab added to standard treatment for its capacity to induce and broaden T cell responses against neo-antigens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: March 5, 2024
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent for the trial.

• Diagnosis of primary stage IV high-grade serous ovarian, peritoneal, or fallopian tube cancer.

• Age >= 18 years on day of signing informed consent.

• Willing and able to provide three tumor biopsies (1 FFPE, 2 fresh frozen) prior to start of treatment

• Performance status of 0 or 1 on the ECOG Performance Scale.

• Adequate organ function as defined in Table 1 of the protocol

• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

Exclusion Criteria:

• Previously received treatment for ovarian, peritoneal, or fallopian tube cancer.

• Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

• Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.

• Known additional malignancy, unless treated with curative intent without chemotherapy at least five years ago. In situ cancers, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone potentially curative therapy within the past five years may also be eligible.

• Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

• A diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

• A known history of active TB (Bacillus Tuberculosis)

• Hypersensitivity to pembrolizumab or any of its excipients.

• Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer Stage IV
• Ovarian Neoplasms
• Peritoneal Cancer

Intervention

Drug:
• Carboplatin
Carboplatin AUC=6
• Paclitaxel
paclitaxel 80 mg/m2
• Pembrolizumab
200 mg flat dose, starting cycle 2

Locations

Country	Name	City	State
Netherlands	Antoni van Leeuwenhoek	Amsterdam

Sponsors (2)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of T-cells in peripheral blood	determine the number of T cells in peripheral blood samples and tissue samples	up to week 52
Secondary	Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0	Toxicity will be analyzed in patients who have received at least one administration of pembrolizumab.	up to 30 days after end of treatment
Secondary	Response Rate	number of patients with no viable invasive tumor left in the resection specimen	at week 12, debulking surgery
Secondary	Response rate according to RECIST	Number of patients with partial or complete response according to RECIST	at week 3 and 6